Corporate News Analysis: The Shocking Collapse of Amaze (AMZE)

Amazingly, the stock of Amaze (AMZE) has plummeted by a staggering ‑21.43 % within a 24‑hour window that closed at 01:13 PM Central Europe on Friday, 23 rd. In a market where investors typically look for stability, this sharp decline is not merely a fluctuation—it is a clear signal of deeper systemic issues that warrant immediate scrutiny.

Current Market Conditions

  • Price: A single share of Amaze is now available for a mere USD 0.01 on the most frequented exchanges.
  • Supply: The float stands at 20.8 million shares—a figure that, in isolation, might suggest liquidity; however, liquidity alone cannot mask a lack of intrinsic value.
  • Market Capitalisation: The company’s market cap is a paltry USD 232.6 k, an indicator that investors no longer recognise Amaze as a valuable asset.
  • Trading Volume: Only USD 9 k worth of shares has changed hands in the last 24 hours, underscoring an erosion of confidence that has reached a critical mass.

Since the end of last month, Amaze has sunk further, losing 92.14 % of its value—a decline that eclipses the performance of many of its peers. Its 200‑day simple moving average sits at USD 1.35, while the highest price in the past year was a lofty USD 9.92 (10/27/2025). The 52‑week low, however, has been reached recently at USD 0.01 (10/21/2026), confirming that the market is no longer willing to pay more than a penny for the stock.

  • Luminar (LAZR.MX): Flat at 0 %, priced at MXN 3.89 with a market cap of MXN 1.4 mn.
  • Evome Medical I (EVMT.V): Flat at 0 %, priced at CAD 0, with a market cap of CAD 302.1 k.
  • 22nd Century (XXII): Down ‑20.88 %, priced at USD 0.22, market cap of USD 194.9 k.
  • Cdt Equity (CDT): Down ‑8.81 %, priced at USD 0.13, market cap of USD 162.7 k.
  • La Rosa (LRHC): Down ‑21.67 %, priced at USD 0.43, market cap of USD 260 k.

While some of these peers have suffered modest declines, Amaze’s performance is an outlier. The company’s failure to sustain even modest growth is a testament to its weak fundamentals, an ineffective strategy, and possibly, a lack of credible leadership.

The Company Behind the Stock

Fresh Vine Wine, Inc.—the parent company of Amaze—is positioned as an American producer of alcoholic beverages, emphasizing low‑carb, low‑calorie, and gluten‑free premium wines. Their product line is exclusively available in the United States, and their brand messaging appears to lean heavily on niche health‑conscious demographics.

However, the company’s business model—while seemingly aligned with contemporary wellness trends—has not translated into profitable revenue streams. The sheer scale of the American market for alcoholic beverages is vast, yet Fresh Vine Wine’s market penetration appears negligible. The company’s reliance on a single product line in a highly saturated market raises red flags about its long‑term viability.

Moreover, the New York Stock Exchange—the venue that once conferred legitimacy upon many nascent enterprises—now reflects a lack of investor confidence. The trading of Amaze on the NYSE is not a marker of success; rather, it underscores a failure to meet the high expectations of the exchange and its participants.

Why Investors Should Be Alarmed

  1. Exponential Decline – A drop of ‑92.14 % over a single month is unprecedented in the current market climate, especially for a listed company.
  2. Liquidity Paradox – Despite a sizable supply, the trading volume remains abysmally low, indicating that the market is effectively “dead.”
  3. Valuation Misalignment – The price-to-earnings ratio (if earnings exist) would be absurdly low, suggesting that the company is undervalued to the point of being worthless.
  4. Competitive Landscape – Fresh Vine Wine faces intense competition from established brands that have already secured market share and brand loyalty.

Conclusion

Amaze’s trajectory is a cautionary tale for investors who chase the next “hot” stock without examining underlying fundamentals. The company’s dramatic price collapse, coupled with its minimal trading activity, signals a crisis that cannot be ignored. The broader lesson is clear: in a world where capital is increasingly allocated to companies that demonstrate sustainable growth, profitability, and robust governance, Amaze has failed to meet even the most basic benchmarks. Investors would do well to reconsider their exposure to this beleaguered stock and to scrutinise the strategic direction of Fresh Vine Wine, Inc. before making further commitments.